Characteristics | eAEs group | Non-eAEs group | P value |
---|---|---|---|
Patients | 16 | 30 | |
Median age at GKRS, years | 49 (21–76) | 48 (11–83) | 0.533a |
Sex (%) | 0.210b | ||
Male | 4 (29.4) | 14 (46.7) | |
Female | 12 (70.6) | 16 (53.3) | |
Laterality (%) | 0.347b | ||
Left | 7 (43.8) | 20 (66.7) | |
Right | 9 (56.2) | 10 (33.3) | |
Tumour component (%) | 0.694b | ||
Solid | 14 (87.5) | 24 (80.0) | |
Cystic | 2 (12.5) | 6 (20.0) | |
Brainstem contact (%) | 11 (68.8) | 18 (60.0) | 0.750b |
Prior microsurgery (%) | 5 (31.3) | 10 (33.3) | 1.000b |
Transient expansion (%) | 11 (68.8) | 5 (16.7) | 0.001b |
Tumour location c (%) | |||
A: Primary intracranial | 2 (12.5) | 14 (46.7) | 0.026b |
B: Jugular foramen with intracranial extension | 1 (6.3) | 2 (6.7) | 1.000b |
C: Primary extracranial with foraminal extension | 2 (12.5) | 7 (23.3) | 0.463b |
D: Intra-/extracranial extension (dumb-bell shaped) | 11 (68.8) | 7 (23.3) | 0.004b |
Median tumour volume, cm3 | 4.85 (2.4–10.8) | 3.1 (0.2–12.3) | 0.003a |
Median follow-up period, months | 48.5 (24–136) | 52 (9–123) | 0.729a |
Median marginal dose, Gy | 13.0 (12.0–14.0) | 13.0 (12.0–14.0) | 0.868a |
Median maximal dose, Gy | 26.2 (24.4–28.7) | 26.1 (24.0–28.7) | 0.641a |